Business
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune CellsEvaluation of Cloak™ Technology to Engineer Allogeneic Cells from Detection by the Host Immune System Preclinical Validation of ALLO-182, an AlloCAR T™ Candidate Targeting Claudin18.2 for the Treatment of Gastric and Pancreatic Cancers SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced three preclinical poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA. These presentations will focus on the Company’s next generation AlloCAR T platform technologies and the foundation for an early-stage solid tumor product candidate, ALLO-182. “We are excited to share some of the groundbreaking work from our research team as we define next generation platform technologies that are designed to enhance engraftment and expansion of our AlloCAR TTM product candidates,” said Zachary Roberts, M.D., Ph.D., Executive Vice President, Research & Development and Chief Medical Officer. “We believe this important and foundational work could expand the potential of off-the-shelf CAR T products by improving their persistence and anti-tumor activity across multiple targets while also creating a path to reducing the intensity of conditioning therapy.” Allogene Abstracts: DAGGER™ PLATFORM TECHNOLOGYPreclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR Presenter: Elvin Lauron, Ph.D. Abstract: 279Poster Session Display Date and Time: Friday, Nov. 3, 2023, 9:00 a.m. - 7:00 p.m. PTLocation: Exhibit Halls A and B1 CLOAK™ PLATFORM TECHNOLOGYGeneration of Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA Transcriptional Regulator RFX5 and Disruption of the Immune Synapse Presenter: Hsin-Yuan Cheng, Ph.D. Abstract: 302Poster Session Display Date and Time: Saturday, Nov. 4, 2023, 9:00 a.m. - 8:30 p.m. PTLocation: Exhibit Halls A and B1 SOLID TUMOR TARGET (ALLO-182)Preclinical Development and Characterization of Allogeneic ...